Apparently, that "same old, same old" shareholder update has...

First 5 Last

Share
Profile

Follow
col69

15,727 Posts.

5757

30/04/21

12:42

Post #: 52844285
Share

Originally posted by Edny ↑

Great! Some how, some way, SPL managed to get to full recruitment on several Phase 2 DEP trials. Would not seem so difficult with proven drugs with a new transport mechanism with demonstrated benefits. So now, let's make some money! Hit the accelerator. No more mission expansion! No additional applications, no more DEP drugs (for now at least), with limited resources. Phase 3 is the big pay day. Let's put a number on the score board. Get one DEP drug to the Phase 2 finish line as quickly as possible.

Which brings us to the question - does the SPL BoD have a strategy? Why do they dither, spreading their resources over so many options? Why do they spend their time and limited staff dabbling in the sales and marketing of Viraleze?
Or do they enjoy R&D so much that they don't want to let go? Is their goal academic tenure or a Nobel prize? Do they not understand their responsibility as a publicly listed company to generate profits?

Apparently, that "same old, same old" shareholder update has pushed my level of frustration with the SPL BoD to new highs...

Expand

Apparently, that "same old, same old" shareholder update has pushed my level of frustration with the SPL BoD to new highs...

And I thought I was a tough critic on management .... lol

So you think the pivot to address the market in India given its current overwhelming medical situation for COVID-19 sufferers outlined in the Shareholder Update is frustrating ?

Sure they still have to pull it off, but with Mundipharma already a distribution partner with an SPL7013 product, it shouldn't be that hard IMO during a pandemic killing thousands a day

SPL Price at posting: $1.70 Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

There are more pages in this discussion • 41 more messages in this thread...

First 5 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.002(1.53%)		Mkt cap ! $41.60M

Open	High	Low	Value	Volume
9.8¢	10.0¢	9.7¢	$28.84K	293.3K

Buyers (Bids)

No.	Vol.	Price($)
1	82	9.9¢

Sellers (Offers)

Price($)	Vol.	No.
10.0¢	223100	7

View Market Depth

No.	Vol.	Price($)
1	82	0.099
1	245200	0.098
1	68758	0.097
1	824859	0.095
2	72280	0.092

Price($)	Vol.	No.
0.100	223100	7
0.105	199684	6
0.110	203882	6
0.115	103392	3
0.120	112305	4

Last trade - 13.59pm 05/11/2024 (20 minute delay)

SPL (ASX) Chart

Apparently, that "same old, same old" shareholder update has...

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Apparently, that "same old, same old" shareholder update has...

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News